Gilead Potential Blockbuster Hep C Drug Wins FDA Nod
[at Investor's Business Daily] - Gilead Potential Blockbuster Hep C Drug Wins FDA Nod
Why Is Actelion Suppressing Phase III Data?
[at Forbes] - I highly recommend a terrific article?by Ian Parker in this week's?New Yorker?about Merck's efforts to develop a novel insomnia drug, suvorexant. Normally I don't write about non-cardiology topics but I want here to call attention to one small, almost tangential detail buried in the middle of the story.?It's not about [...]
Top Equity Research Analyst Interviews of 2013: Significant Stock Price Appreciation and Increased M&A from Biotech Productivity and Innovation
[Wall Street Transcript] - 67 WALL STREET, New York - December 6, 2013 - The Wall Street Transcript has just published its Top Ten Equity Analyst Interviews 2013 Report. This special feature contains expert industry commentary through ...
Treating Allergies With Pills or Drops Instead of Shots
[at New York Times] - Two companies are asking the Food and Drug Administration for approval to market tablets or liquids to treat allergies, drugs which are already available in Europe.
4 Potential Blockbuster Drugs Awaiting Launch
[at Investor's Business Daily] - 4 Potential Blockbuster Drugs Awaiting Launch